血管紧张素受体脑啡肽酶抑制剂在心力衰竭中的研究进展(3)
[7] Packer M，Mcmurray J J，Desai A S，et al.Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.[J].Circulation，2015，131(1)：54-61.
[8] Velazquez E J，Morrow D A，DeVore A D，et al.Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure[J].New England Journal of Medicine，2018.
[9] Jhund P S，McMurray J J V.The neprilysin pathway in heart failure：a review and guide on the use of sacubitril/valsartan[J].Heart，2016，102(17)：1342-1347.
[10] Yancy C W，Januzzi J L，Allen L A，et al.2017 ACC expert consensus decision pathway for optimization of heart failure treatment：answers to 10 pivotal issues about heart failure with reduced ejection fraction：a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways[J].Journal of the American College of Cardiology，2018，71(2)：201-230.
[11] Solomon S D，Zile M，Pieske B，et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction：a phase 2 double-blind randomised controlled trial[J].The Lancet，2012，380(9851)：1387-1395.
本文編辑：赵小龙, 百拇医药(张龙飞 王鹏 龙积丽 曹雪滨)
[8] Velazquez E J，Morrow D A，DeVore A D，et al.Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure[J].New England Journal of Medicine，2018.
[9] Jhund P S，McMurray J J V.The neprilysin pathway in heart failure：a review and guide on the use of sacubitril/valsartan[J].Heart，2016，102(17)：1342-1347.
[10] Yancy C W，Januzzi J L，Allen L A，et al.2017 ACC expert consensus decision pathway for optimization of heart failure treatment：answers to 10 pivotal issues about heart failure with reduced ejection fraction：a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways[J].Journal of the American College of Cardiology，2018，71(2)：201-230.
[11] Solomon S D，Zile M，Pieske B，et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction：a phase 2 double-blind randomised controlled trial[J].The Lancet，2012，380(9851)：1387-1395.
本文編辑：赵小龙, 百拇医药(张龙飞 王鹏 龙积丽 曹雪滨)